

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

COMPLETION OF MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF THE ENTIRE ISSUED SHARE CAPITAL IN PHC MEDICAL DIAGNOSTIC CENTRE LIMITED AND PREMIER MEDICARE SERVICES LIMITED

References are made to the announcements of China Biotech Services Holdings Limited (the “**Company**”) dated 18 May 2026, 2 June 2026, 9 June 2026, 26 June 2026 and 29 June 2026 respectively (the “**Announcements**”) and the circular (the “**Circular**”) of the Company dated 30 June 2026, in relation to, among others, the Disposal. Unless otherwise stated, capitalised terms used herein shall have the same meanings as defined in the Announcements and the Circular.

The Board is pleased to announce that all the conditions precedent set out in the Sale and Purchase Agreement have been fulfilled and Completion took place on 13 August 2026 in accordance with the terms and conditions of the Sale and Purchase Agreement. Immediately upon Completion and as at the date of this announcement, each of PHC and PMS has ceased to be a subsidiary of the Group and the financial results of each of PHC and PMS will no longer be consolidated into those of the Group.

The Disposal of the laboratory testing business represents a key milestone in the Group’s implementation of its business strategic transformation. By disposing of the continuously loss-making Hong Kong laboratory testing business, the Group is able to reallocate its human, financial and operational resources to focus on the development of the full industry chain of boron neutron capture therapy (“**BNCT**”) medical services, BNCT drugs and equipment, with a view to building a BNCT technology industrial platform of international standards and leading domestically.

By Order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 13 August 2026

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Liu Xiaolin (Chairman), Dr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.